TrialsgrambetaRCTs are beautiful

RAVE

2010

Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis

In 197 patients with severe ANCA-associated vasculitis, rituximab was non-inferior for inducing remission compared with cyclophosphamide.

Result

Complete remission without steroids at month 6
Absolute difference
11 points

The absolute difference is derived from the event rates.

Also reported: (non-inferior); superior in the relapsing subgroup.

Original publication
Subtopic
ANCA vasculitis
Design
Double-blind, double-dummy RCT
Relevance
Practice-defining: a trial the guidelines cite as evidence.
Source
Stone JH, et al. N Engl J Med. 2010;363(3):221-232.doi 10.1056/NEJMoa0909905

Discussion & critique

Established rituximab as standard induction in ANCA vasculitis, sparing cyclophosphamide exposure.

Discussed in podcasts